Monopar Therapeutics (NASDAQ:MNPR) Downgraded to “Sell” Rating by Wall Street Zen

Wall Street Zen lowered shares of Monopar Therapeutics (NASDAQ:MNPR) from a hold rating to a sell rating in a report published on Saturday morning.

Other research analysts have also issued reports about the stock. Leerink Partnrs upgraded shares of Monopar Therapeutics to a “strong-buy” rating in a report on Monday, November 10th. HC Wainwright set a $105.00 price target on shares of Monopar Therapeutics and gave the stock a “buy” rating in a research note on Monday, September 29th. Jones Trading raised shares of Monopar Therapeutics from a “hold” rating to a “strong-buy” rating in a research note on Friday, October 10th. Cantor Fitzgerald restated an “overweight” rating on shares of Monopar Therapeutics in a report on Wednesday, September 24th. Finally, Oppenheimer set a $115.00 target price on Monopar Therapeutics and gave the stock an “outperform” rating in a research report on Thursday, October 2nd. Two equities research analysts have rated the stock with a Strong Buy rating, eleven have assigned a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Buy” and a consensus target price of $107.00.

Monopar Therapeutics Stock Down 0.6%

Shares of NASDAQ:MNPR opened at $63.00 on Friday. The company has a market cap of $420.84 million, a P/E ratio of -18.31 and a beta of 1.46. The business has a fifty day simple moving average of $76.02 and a 200-day simple moving average of $62.23. Monopar Therapeutics has a 52 week low of $24.00 and a 52 week high of $105.00.

Monopar Therapeutics (NASDAQ:MNPR) last released its earnings results on Thursday, November 13th. The company reported ($0.48) earnings per share for the quarter, missing the consensus estimate of ($0.46) by ($0.02). Sell-side analysts expect that Monopar Therapeutics will post -1.65 earnings per share for the current fiscal year.

Insider Activity at Monopar Therapeutics

In other Monopar Therapeutics news, CFO Quan Anh Vu bought 1,500 shares of Monopar Therapeutics stock in a transaction that occurred on Friday, December 26th. The shares were acquired at an average price of $69.95 per share, for a total transaction of $104,925.00. Following the acquisition, the chief financial officer owned 1,500 shares of the company’s stock, valued at $104,925. The trade was a ∞ increase in their position. The acquisition was disclosed in a filing with the SEC, which can be accessed through this link. Corporate insiders own 20.50% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in the stock. Russell Investments Group Ltd. acquired a new position in shares of Monopar Therapeutics during the third quarter worth about $28,000. Police & Firemen s Retirement System of New Jersey purchased a new stake in shares of Monopar Therapeutics during the 2nd quarter valued at about $34,000. BNP Paribas Financial Markets raised its holdings in shares of Monopar Therapeutics by 100.6% during the 3rd quarter. BNP Paribas Financial Markets now owns 696 shares of the company’s stock valued at $57,000 after buying an additional 349 shares during the period. AlphaQuest LLC lifted its position in Monopar Therapeutics by 46.8% during the 2nd quarter. AlphaQuest LLC now owns 1,784 shares of the company’s stock worth $64,000 after acquiring an additional 569 shares in the last quarter. Finally, JPMorgan Chase & Co. boosted its holdings in Monopar Therapeutics by 1,821.0% in the 2nd quarter. JPMorgan Chase & Co. now owns 1,921 shares of the company’s stock worth $69,000 after acquiring an additional 1,821 shares during the period. 1.83% of the stock is owned by hedge funds and other institutional investors.

About Monopar Therapeutics

Monopar Therapeutics, Inc is a clinical-stage biotechnology company focused on the development of novel targeted radiotherapeutics and next-generation antibody-drug conjugates for the treatment of cancer. The company’s core technology leverages a pretargeted radioimmunotherapy (PRIT) platform designed to deliver potent radioisotopes to tumor cells while minimizing exposure to healthy tissues. By combining small-molecule binding agents with specialized radioisotopes, Monopar aims to improve the therapeutic index of radiation-based cancer therapies.

The company’s pipeline includes multiple oncology candidates in various stages of preclinical and early clinical development.